AZ
AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients
November 12, 2020Business Services AZ, AstraZeneca, Calquence
AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19. Calquence (acalabrutinib) is …
European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine
October 9, 2020Medical Communications AZ, AstraZeneca, Janssen
The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s …
AstraZeneca’s Brilinta reduces the rate of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack
July 16, 2020Business Services AZ, AstraZeneca, drug trials
AstraZeneca’s Phase 3 THALES trial showed that Brilinta (ticagrelor) significantly reduced the rate of death or stroke in patients with …
AstraZeneca invests “tens of millions” into Cheshire, UK manufacturing site
August 29, 2017Manufacturing and Production, Research and Development AZ, AstraZeneca, Cheshire, Chesire, UK, life sciences, pharma, pharmaceuticals
AstraZeneca has announced plans to invest a multi-million sum into its £150 million facility in Macclesfield, Chesire, UK – a …
GSK’s new President of Global Pharma join date revealed as AZ drops lawsuit
June 20, 2017Business Services, Manufacturing and Production AZ, AstraZeneca, GSK, GlaxoSmithKline, Luke Miels
The transition of former AstraZeneca Executive Vice President for Europe Luke Miels to rival pharma giant GlaxoSmithKline has not been …
AZ launches lawsuit against former executive for defecting to GSK
May 17, 2017Manufacturing and Production, Research and Development AZ, AstraZeneca, GSK, GlaxoSmithKline
AstraZeneca has launched a lawsuit against one of its former executives after he jumped ship to join rival pharma giant …
Major pharma firms join Liverpool Uni in £14m pharmacovigilance project
January 30, 2017Research and Development, Sales and Marketing AZ, AbbVie, Eli Lilly, GSK, University of Liverpool, pharmacovigilance
The UK’s University of Liverpool is to launch a £14 million pharmacovigilance project focused on using new modelling approaches to …
AZ and Lilly come together to battle Alzheimer’s
December 9, 2016Research and Development, Sales and Marketing AZ, lilly
Pharma titans Eli Lilly and AstraZeneca have announced they are to join forces to co-develop a potential Alzheimer’s treatment, currently …
AZ reveals compelling PhIII data for ovarian cancer treatment
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …
AZ “disappointment” at heart drug failure
October 5, 2016Research and Development AZ, AstraZeneca, trial failure
AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
Analysts predict Pfizer to swallow GSK
May 21, 2015Sales and Marketing AZ, GSK, GlaxoSmithKline, Pfizer, merger
GlaxoSmithKline has been suggested as a potential M&A target for Pfizer, despite the US company backing out of a similar …
AstraZeneca eyes success in immuno-oncology combinations
May 14, 2015Sales and Marketing ASCO, AZ, AstraZeneca, CTLA-4, MEDI4736
An investigational immuno-oncology drug combination from AstraZeneca has shown promise in its most recent trial, although concerns over its side …
Pharma reveals its ASCO presentation data
May 12, 2015Research and Development, Sales and Marketing ASCO, AZ, AbbVie, Roche, chicago, data
AstraZeneca, Genentech and AbbVie have all revealed which cancer drugs they will show data for at The American Society of …
AstraZeneca lung drug shows promise
April 20, 2015Sales and Marketing AZ, AZD9291, AstraZeneca, European Lung Cancer Congress, NSCLC, Orphan
AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
